Drugs & Targets Cullinan Oncology, Mount Sinai partner to advance novel small molecule immune modulators January 14, 2022Vol.48 No.02
Drugs & Targets FDA clears IND for P-MUC1C-ALLO1, a fully allogeneic CAR T targeting multiple solid tumors January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Breakthrough Therapy designation for CLN-081 in locally advanced or metastatic EGFR-mutated NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets FDA grants Fast Track designation for Reqorsa with Keytruda in NSCLC January 07, 2022Vol.48 No.01
Drugs & Targets Rain Therapeutics, Roche to collaborate on clinical trial of milademetan combination with anti-PD-L1 immunotherapy for solid tumors January 07, 2022Vol.48 No.01
Drugs & TargetsFree FDA approves Orencia for prevention of acute graft vs. host disease following unrelated donor HSCT December 17, 2021Vol.47 No.46
Drugs & TargetsFree EU CHMP adopts positive opinion for Keytruda as adjuvant therapy in RCC following surgery December 17, 2021Vol.47 No.46
Drugs & TargetsFree Inceptor Bio in-licenses CAR-M Technology from UCSB December 17, 2021Vol.47 No.46
Drugs & Targets FDA approves Rituxan plus chemo for pediatric cancer indications December 10, 2021Vol.47 No.45
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for BRAF inhibitor therapeutics in melanoma December 10, 2021Vol.47 No.45
